semaglutide and graves disease Can (Ozempic) be used in a patient with active disease, what precautions or alternative therapies should be considered until euthyroidism is achieved? GLP-1 Medications and Autoimmune Thyroid

GLP-1 Receptor Modulation Appetite Regulation and Glucose Control Activation of glucagon-like peptide-1 (GLP-1) receptors by GLP3 contributes to multiple metabolic effects observed in clinical studies[6]: Delayed gastric emptying , resulting in prolonged satiety and reduced meal size Suppression of appetite through actions on hypothalamic feeding centers Enhancement of glucose-stimulated insulin secretion from beta cells Inhibition of glucagon secretion from pancreatic alpha cells during hyperglycemic states Potential neuroprotective effects through central nervous system GLP-1 receptor engagement Phase 1b studies in humans with type 2 diabetes confirmed that GLP3 significantly delays gastric emptying, with effects persisting throughout the 12-week treatment period, suggesting limited tachyphylaxis development compared to some other GLP-1 receptor agonists[7]

doi: 10.1210/en.2011-1687

Be prepared for modest but meaningful changes if the conditions are right

Porter DE, Prasad V, Foster L, Dall GF, Birch R, Grimer RJ